• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis

byDavy LauandAlex Chan
February 6, 2023
in Chronic Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

Black patients with pulmonary fibrosis may have worse outcomes compared to other populations

1. For patients with idiopathic pulmonary fibrosis (IPF), there was no difference in pulmonary function and efficacy between patients on low-dose pirfenidone compared to standard dose.

2. Patients on low-dose pirfenidone were more likely to be older than those on standard dose, and were also more likely to report experiencing gastrointestinal and skin side effects.

Evidence Rating Level: 2 (Good)

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of 3-5 years. While the antifibrotic drug pirfenidone is known to decrease decline of lung function in IPF patients, it is also associated with adverse gastrointestinal and skin-related events. Although some studies suggest low-dose pirfenidone is non-inferior to standard dosing, the burden of adverse side effects in low-dose pirfenidone is not well-known. Therefore, this single-centre study based in South Korea aimed to elucidate the factors associated with pirfenidone dose reduction. The study population consisted of IPF patients treated with pirfenidone, with 1 or more follow-up visits that assessed for adverse side effects. In this study, a standard dose was considered 1800 mg/day, whereas low-dose was less than 1800 mg/day. In total, there were 156 patients included, with a mean age of 69.7 years, and a median (IQR) follow-up of 243 (84-385) days. The study found that those taking low-dose pirfenidone were more likely older (71.0 years vs 67.4 years, p = 0.016), less likely to be ever-smokers (80.8% vs 96.4%, p = 0.008), and more likely to have a lower BMI (24.1 kg/m2 vs 25.7 kg/m2, p = 0.027). There were no differences in pulmonary fit test results, exercise capacity, or rates of pulmonary hypertension between the standard and low-dose groups, though more patients on standard dosing had emphysema (p = 0.048). After adjusting for sex, BMI, smoking status, and emphysema, older age was associated with reduction of pirfenidone dose (OR 1.066, p = 0.016). In addition, there were higher rates of some adverse events reported in the low-dose compared to the standard dose group, including anorexia (20.5% vs 3.5%, p = 0.004), urticaria (24.7% vs 10.5%, p = 0.039), and generalized weakness (9.6% vs 0.0%, p = 0.018). More broadly, the low-dose group experienced higher rates of gastrointestinal side effects (p < 0.01) and skin side effects (p = 0.020) than the standard group. Overall, this study demonstrated that older patients were more likely to be on low-dose pirfenidone, and that individuals in the low-dose group were more likely to experience side effects, though there were no differences in pulmonary function and efficacy of pirfenidone between the groups.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ildpulmonary fibrosispulmonology
Previous Post

Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease

Next Post

Former professional football players may be at greater risk of chronic disease

RelatedReports

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Quick Take: Discovery and validation of a prognostic proteomic signature for tuberculosis progression
Chronic Disease

Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

March 17, 2023
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Chronic Disease

Black patients with pulmonary fibrosis may have worse outcomes compared to other populations

March 16, 2023
Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]
Chronic Disease

Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

March 14, 2023
Next Post
Few differences in location-stratified football-related concussions

Former professional football players may be at greater risk of chronic disease

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: Maternity Leave Left Out, Dry January, A Measles Resurgence, Dr. GPT

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Faecal haemoglobin concentrations associated with mortality and cause of death in colorectal cancer screening

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options